Tipranavir Articles
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Aptivus achieves SVR in treatment-experienced children
18 August 2008
HIV/AIDS drug prices frozen for US agencies
9 June 2008
Aptivus gives durable response in HIV patients
5 November 2007
Strong female-specific data for Aptivus
6 August 2007
Boeh Ing initiates Ph IIIb Aptivus study
25 June 2007
Aptivus resistant HIV still responds to darunavir
12 March 2007
Promising long-term data for Boehringer's Aptivus
20 November 2006
CORRECTION: IAS HIV treatment guidelines
4 September 2006
BI's Aptivus linked to intracranial bleeding
10 July 2006
AHF slams "record-high" price rise for BI's Aptivus
5 September 2005
Positive CHMP opinion for BI
8 August 2005
FDA committee OKs BI's tipranavir for HIV
6 June 2005
Boeh Ingelheim files NDA for tipranavir
1 November 2004
Boeh Ingelheim starts two mega-trials
24 February 2003
Boeh Ingelheim's tipranavir for PI resistance
24 February 2003
Boehringer's tipranavir effective in resistant HIV
15 July 2002
BI's tipranavir effective in resistant HIV
11 March 2002
BI's tipranavir effective as HIV salvage regimen
10 July 2001
Boehringer's tipranavir shows early promise in HIV
15 March 2001
BI acquires new HIV drug from P&U
2 February 2000
P&U's tipranavir combats resistant HIV
25 June 1999
New product line up at Pharmacia & Upjohn
16 April 1999
Showing 1-37 of 37 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
